Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

Yongting Lai; Bing Feng; Mubalake Abudoureyimu; Yingru Zhi; Hao Zhou; Ting Wang; Xiaoyuan Chu; Ping Chen; Rui Wang

doi:10.3389/fonc.2019.01156

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

Front Oncol. 2019 Nov 5:9:1156. doi: 10.3389/fonc.2019.01156. eCollection 2019.

Authors

Yongting Lai¹, Bing Feng², Mubalake Abudoureyimu², Yingru Zhi², Hao Zhou³, Ting Wang², Xiaoyuan Chu^{1

2}, Ping Chen⁴, Rui Wang^{1

2}

Affiliations

¹ Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China.
² Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.
³ Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China.
⁴ Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China.

Abstract

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC.

Keywords: hepatocellular carcinoma (HCC); long non-coding RNAs (lncRNAs); microRNAs (miRNAs); non-coding RNAs (ncRNAs); sorafenib resistance.

Publication types

Review